Has Leonard Gomella, MD received payments from drug or device companies?

Yes. Drug and device makers reported $190,404 in general payments to Leonard Gomella, MD across 126 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Leonard Gomella, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Leonard Gomella, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Leonard Gomella, MD

Urology · Philadelphia, PANPI 1598781601

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $167,355 of the $190,404 with a category attached, or 87.9%. 23 manufacturers reported payments, led by Merck at 35.8% of the total. Among urology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$190,404in general payments, 2019–2025

Across 126 payments — averaging $1511.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Merck$68K
Johnson & Johnson$46K
Progenics Pharmaceuticals, Inc.$14K
Bayer$11K
Janssen Scientific Affairs, LLC$10K
Ferring Pharmaceuticals Inc.$8K
plus $34K from 17 others

$2,051in research payments, 2019–2025

Across 1 payment — averaging $2051.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Astellas Pharma Global Development$2K

What the payments were for

Consulting fees$167,35588%
Speaking & faculty fees$16,0688%
Travel & lodging$3,8812%
Food & beverage$2,9592%
Education$1400%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Merck	42	$68,077
Johnson & Johnson	2	$46,090
Progenics Pharmaceuticals, Inc.	10	$13,761
Bayer	9	$10,548
Janssen Scientific Affairs, LLC	12	$9,983
Ferring Pharmaceuticals Inc.	5	$8,045
Astrazeneca UK Limited	4	$7,787
Astellas Pharma US Inc	6	$4,801
Exelixis Inc.	1	$3,960
Bristol Myers Squibb	3	$3,805
Clovis Oncology, Inc.	7	$3,156
AbbVie	2	$2,906
Ambu Inc.	3	$2,744
Blue Earth Diagnostics	1	$2,400
Pfizer	4	$1,495
EDAP Technomed Inc	5	$254
Teleflex LLC	2	$196
Servier Pharmaceuticals LLC	2	$170
Baxter Healthcare	1	$98
Photocure Inc	2	$39
C. R. Bard, Inc. & Subsidiaries	1	$36
Telix Pharmaceuticals	1	$29
Boston Scientific	1	$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

PYLARIFY$13,560
Erleada$9,726
Non-Covered$6,326
XTANDI$6,064
LYNPARZA$4,629
Nubeqa$4,018
Cabometyx$3,960
CC-90011$3,710
Rubraca$3,043
Lupron Depot$2,888
POSLUMA$2,400
ADSTILADRIN$1,108
ASPARLAS$114

How this compares

$190,404 in reported general payments places this provider in the 95th percentile of 596 urology providers in Pennsylvania.

See all urology providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$45,692

Medicare patients

194

Services billed

397

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Tamsulosin Hcl	81	$2,115
Finasteride	44	$998
Dutasteride	18	$488
Sildenafil Citrate	12	$81

Paid to pharmacies, not to this prescriber.

Other urology in Philadelphia

Demetrius BagleyPhiladelphia$739K
Daniel EunPhiladelphia$226K
Phillip GinsbergPhiladelphia$145K
Edouard TrabulsiPhiladelphia$137K
Siobhan HartiganPhiladelphia$121K
Paul ChungPhiladelphia$120K
William JaffePhiladelphia$119K
Robert UzzoPhiladelphia$111K
Jay SimhanPhiladelphia$110K
Trinity BivalacquaPhiladelphia$100K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →